keyword
MENU ▼
Read by QxMD icon Read
search

oral tolerance

keyword
https://www.readbyqxmd.com/read/29331760/inotodiol-suppresses-proliferation-of-breast-cancer-in-rat-model-of-type-2-diabetes-mellitus-via-downregulation-of-%C3%AE-catenin-signaling
#1
Xia Zhang, Cuiyu Bao, Jingping Zhang
Breast cancer is amongst the most common cancers causing death of women worldwide. Breast cancer occurrence is more prominent in people with diabetes. A recent trend is management of diabetes and cancer has evolved to be natural remedy including single molecule therapy or combination. In this study, we investigated the effect of inotodiol on breast cancer growth in diabetic conditions. Inotodiol is a lanostane triterpenoid found in natural resources like edible mushroom Inonotus obliquus. We established a rat model of diabetic-breast cancer by treating female Sprague-Dawley rats with streptazotocin (STZ) at 35 mg/kg followed by induction of breast cancer by administration of 7,12-dimethylbenz(a)anthracene (DMBA) at 10 mg/kg...
January 10, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29331510/effects-of-sub-minimum-inhibitory-concentrations-of-lemon-essential-oil-on-the-acid-tolerance-and-biofilm-formation-of-streptococcus-mutans
#2
Yanwei Sun, Sijia Chen, Chen Zhang, Yali Liu, Li Ma, Xiangyu Zhang
OBJECTIVES: Lemon essential oil (LEO) is a kind of secondary metabolite from lemon peels and has been found to inhibit cariogenic bacteria for decades. However, its effects on main cariogenic virulence factors are rarely reported. The present study aimed to investigate the effects of sub-minimum inhibitory concentrations (sub-MICs) of LEO on the acid tolerance and biofilm formation of Streptococcus mutans (S. mutans) and preliminarily reveal the possible underlying mechanisms. DESIGNS: Effects of LEO on the acid tolerance and biofilm formation of S...
December 29, 2017: Archives of Oral Biology
https://www.readbyqxmd.com/read/29330841/delayed-replantation-of-an-avulsed-immature-permanent-incisor-and-apexification-using-a-novel-fast-setting-calcium-silicate-cement-containing-fluoride-a-3-year-follow-up-case-report
#3
A Vafaei, B Ranjkesh, L Erfanparast, H Løvschall
BACKGROUND: Traumatic tooth avulsion requires an urgent intervention to replant the tooth. Prolonged post-injury dry extra-oral conditions worsen the prognosis and increase the risk of root resorption. Fluoride has the potential to delay replacement resorption. Calcium silicate cements (CSC) are used to seal the root canal system and to stimulate periapical regeneration in immature open apex teeth (apexification). This report suggests the application of a novel fast-setting CSC with fluoride for apexification in an attempt to hinder root resorption...
January 12, 2018: European Archives of Paediatric Dentistry: Official Journal of the European Academy of Paediatric Dentistry
https://www.readbyqxmd.com/read/29330005/a-phase-i-study-of-irinotecan-capecitabine-xeloda-and-oxaliplatin-in-patients-with-advanced-colorectal-cancer
#4
Jean Maroun, Horia Marginean, Derek Jonker, Christine Cripps, Rakesh Goel, Timothy Asmis, Rachel Goodwin, Gabriela Chiritescu
BACKGROUND: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC). PATIENTS AND METHODS: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle...
December 15, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29329957/safety-and-tolerability-of-a-novel-polyclonal-human-anti-mers-coronavirus-antibody-produced-from-transchromosomic-cattle-a-phase-1-randomised-double-blind-single-dose-escalation-study
#5
John H Beigel, Jocelyn Voell, Parag Kumar, Kanakatte Raviprakash, Hua Wu, Jin-An Jiao, Eddie Sullivan, Thomas Luke, Richard T Davey
BACKGROUND: Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from the hyperimmune plasma of transchromosomic cattle immunised with a MERS coronavirus vaccine...
January 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29329493/a-randomized-double-blind-controlled-trial-of-intravenous-meloxicam-in-the-treatment-of-pain-following-dental-impaction-surgery
#6
Steven E Christensen, Stephen A Cooper, Randall J Mack, Stewart W McCallum, Wei Du, Alex Freyer
This randomized, controlled phase 2 study was conducted to evaluate the analgesic efficacy, safety, and tolerability of single intravenous (IV) doses of 15 mg, 30 mg, and 60 mg meloxicam compared with oral ibuprofen 400 mg and placebo after dental impaction surgery. The primary efficacy end point was the sum of time-weighted pain intensity differences for 0-24 hours postdose. Among 230 evaluable subjects, meloxicam IV 60 mg produced the greatest reduction in pain, followed by the 30-mg and 15-mg doses. Statistically significant differences in summed pain intensity differences over 24 hours were demonstrated for each active-treatment group vs placebo (favoring active treatment) and for meloxicam IV 30 mg and 60 mg vs ibuprofen 400 mg (favoring meloxicam IV)...
January 12, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29329482/pharmacokinetics-of-rolapitant-in-patients-with-mild-to-moderate-hepatic-impairment
#7
Jing Wang, Xiaodong Wang, Zhi-Yi Zhang, Sujata Arora, Sharon Lu, Vikram Kansra
Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. This was a phase 1 open-label, parallel-group pharmacokinetic and safety study of a single oral dose of 180 mg of rolapitant and its major active metabolite, M19, in subjects with mild and moderate hepatic impairment compared with healthy matched controls. Pharmacokinetics were assessed by a mixed-model analysis of variance of log-transformed values for maximum observed plasma concentration (Cmax ), observed time at Cmax (tmax ), area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-t ), and AUC from time 0 to 120 hours (AUC0-120 ), with hepatic group as a fixed effect...
January 12, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29328940/first-trimester-serum-biomarkers-to-predict-gestational-diabetes-in-a-high-risk-cohort-striving-for-clinically-useful-thresholds
#8
Siobhan M Corcoran, Natalie Achamallah, John O' Loughlin, Philip Stafford, Pat Dicker, Fergal D Malone, Fionnuala Breathnach
OBJECTIVES: Screening and diagnosis of gestational diabetes (GDM) has been a source of controversy. The prevalence has increased in line with an obesity epidemic and a trend towards delayed child-bearing. Treatment of even modest glycaemic impairment in pregnancy has been shown to be beneficial in preventing its clinical sequalae. However the cumbersome nature and timing of the oral glucose tolerance test coupled with debate around universal versus risk factor based screening have been problematic...
January 1, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29327780/systematic-review-with-meta-analysis-effectiveness-and-tolerability-of-interferon-free-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-genotype-1-in-routine-clinical-practice-in-asia
#9
REVIEW
F Ji, B Wei, Y H Yeo, E Ogawa, B Zou, C D Stave, Z Li, S Dang, N Furusyo, R C Cheung, M H Nguyen
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017...
January 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29327400/a-vitamin-b12-conjugate-of-exendin-4-improves-glucose-tolerance-without-associated-nausea-or-hypophagia-in-rodents
#10
Elizabeth G Mietlicki-Baase, Claudia G Liberini, Jayme L Workinger, Ron L Bonaccorso, Tito Borner, David J Reiner, Kieran Koch-Laskowski, Lauren E McGrath, Rinzin Lhamo, Lauren M Stein, Bart C De Jonghe, George G Holz, Christian L Roth, Robert P Doyle, Matthew R Hayes
AIMS: While pharmacological glucagon-like peptide-1 receptor (GLP-1R) agonists are FDA-approved for treating type 2 diabetes mellitus (T2DM) and obesity, a major side effect is nausea/malaise. We recently developed a conjugate of vitamin B12 bound to the GLP-1R agonist exendin-4 (Ex4), which displays enhanced proteolytic stability and retention of GLP-1R agonism. Here, we evaluate whether the conjugate (B12-Ex4) can improve glucose tolerance without producing anorexia and malaise. MATERIALS AND METHODS: We evaluated the effects of systemic B12-Ex4 and unconjugated Ex4 on food intake and body weight change, oral glucose tolerance, and nausea/malaise in male rats, and on intraperitoneal glucose tolerance in mice...
January 12, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29327075/phase-ii-study-of-sorafenib-combined-with-concurrent-hepatic-arterial-infusion-of-oxaliplatin-5-fluorouracil-and-leucovorin-for-unresectable-hepatocellular-carcinoma-with-major-portal-vein-thrombosis
#11
Min-Ke He, Ru-Hai Zou, Qi-Jiong Li, Zhong-Guo Zhou, Jing-Xian Shen, Yong-Fa Zhang, Zi-Shan Yu, Li Xu, Ming Shi
BACKGROUND: Sorafenib is recommended for the first-line treatment of advanced hepatocellular carcinoma (HCC). However, the median progression-free survival (PFS) of patients with HCC and major portal vein tumor thrombosis treated with sorafenib monotherapy is no more than 3 months. A prospective single-arm phase II study was conducted to determine whether adding hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin to sorafenib could improve on these results...
January 11, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29326420/fasting-and-glucose-induced-thermogenesis-in-response-to-three-ambient-temperatures-a-randomized-crossover-trial-in-the-metabolic-syndrome
#12
K Pathak, R J Woodman, A P James, M J Soares
BACKGROUND/OBJECTIVES: Cold exposure increases thermogenesis and could improve insulin sensitivity. We hypothesized a blunted response in the metabolic syndrome (MetS). SUBJECTS/METHODS: Twenty older adults 59 ± 10.4 years (with MetS, MetS+, n = 9; without MetS, MetS-, n = 11) completed a randomized crossover design of 3.5 h exposures to 20, 25 and 27 °C on three visits. After an hour's rest at the desired temperature, resting metabolic rate (RMR), respiratory quotient (RQ), forearm to fingertip gradients (FFG), and in the ear temperature (IET) were measured over 30 min...
January 11, 2018: European Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/29326107/tcf7l2-genetic-variation-augments-incretin-resistance-and-influences-response-to-a-sulfonylurea-and-metformin-the-study-to-understand-the-genetics-of-the-acute-response-to-metformin-and-glipizide-in-humans-sugar-mgh
#13
Shylaja Srinivasan, Varinderpal Kaur, Bindu Chamarthi, Katherine R Littleton, Ling Chen, Alisa K Manning, Jordi Merino, Melissa K Thomas, Margo Hudson, Allison Goldfine, Jose C Florez
OBJECTIVE: The rs7903146 T allele in transcription-factor-7-like-2 (TCF7L2) is strongly associated with type 2 diabetes (T2D), but the mechanisms for increased risk remain unclear. We evaluated the physiologic and hormonal effects of TCF7L2 genotype before and after interventions that influence glucose physiology. RESEARCH DESIGN AND METHODS: We genotyped rs7903146 in 608 individuals without diabetes and recorded biochemical data before and after one dose of glipizide (5 mg) on visit 1, and a 75-g oral glucose tolerance test (OGTT) performed after administration of metformin 500 mg twice daily over 2 days...
January 11, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29325996/direct-acting-antiviral-therapy-for-hepatitis-c-virus-infection-in-the-kidney-transplant-recipient
#14
REVIEW
Donald F Chute, Raymond T Chung, Meghan E Sise
Hepatitis C virus infection (HCV) is a common comorbidity in patients who have undergone kidney transplantation and is associated with increased morbidity and mortality compared with recipients who do not have chronic HCV infection. Because interferon-α-based therapies can precipitate acute rejection, they are relatively contraindicated after kidney transplantation. Thus, the majority of kidney transplant recipients with HCV remain untreated. There are now all-oral, interferon-free direct-acting antiviral therapies for HCV infection that are extremely effective and well tolerated in the general population...
January 9, 2018: Kidney International
https://www.readbyqxmd.com/read/29325728/myo-inositol-lowers-the-risk-of-developing-gestational-diabetic-mellitus-in-pregnancies-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials-with-trial-sequential-analysis
#15
REVIEW
Xianshan Guo, Shizhe Guo, Zhiyi Miao, Zhen Li, Hongya Zhang
AIMS: to explore the potential benefit of myo-inositol on pregnant women with high risk of developing gestational diabetes mellitus (GDM). METHODS: Pubmed, Embase, and Cochrane library were systematically searched for randomized controlled trials (RCTs) comparing myo-inositol with placebo for pregnant women with risk factors of GDM. Primary outcome were the incidence of GDM and birth weight. Secondary outcomes included fasting, 1h, and 2h oral glucose tolerance test (OGTT), and complications...
July 21, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/29325686/phase-ii-study-of-tailored-s-1-monotherapy-with-a-1-week-interval-after-a-2-week-dosing-period-in-elderly-patients-with-advanced-non-small-cell-lung-cancer
#16
Hisatsugu Goto, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Fumitaka Ogushi, Takashi Haku, Takanori Kanematsu, Tomoyuki Urata, Soji Kakiuchi, Masaki Hanibuchi, Saburo Sone, Yasuhiko Nishioka
BACKGROUND: S-1 is an oral fluoropyrimidine that is active in the treatment of non-small cell lung cancer (NSCLC); however, an optimal treatment schedule and appropriate dose adjustments of S-1 in elderly patients have not yet been established. METHODS: We conducted a phase II trial to evaluate the efficacy and safety of a 2-week S-1 monotherapy treatment followed by a 1-week interval as a first-line treatment of elderly NSCLC patients, by adjusting the dose based on the individual creatinine clearance (Ccr) and body surface area (BSA)...
January 2018: Respiratory Investigation
https://www.readbyqxmd.com/read/29325675/mycophenolate-mofetil-as-a-therapeutic-agent-for-interstitial-lung-diseases-in-systemic-sclerosis
#17
REVIEW
Takahiro Ueda, Takuro Sakagami, Toshiaki Kikuchi, Toshinori Takada
Systemic sclerosis (SSc) is an intractable disease that causes fibrosis in all organs. Approximately 40% of patients with SSc have some degree of interstitial lung disease (ILD). One third of patients with SSc and ILD, approximately 15% of all patients, have pulmonary lesions, which slowly progress to respiratory failure resistant to corticosteroid and other treatments. A randomized controlled trial conducted in the United States indicated that one year of treatment with oral cyclophosphamide in patients with SSc-ILD had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and health-related quality of life...
January 2018: Respiratory Investigation
https://www.readbyqxmd.com/read/29324870/incretin-responses-to-oral-glucose-and-mixed-meal-tests-and-changes-in-fasting-glucose-levels-during-7-years-of-follow-up-the-hoorn-meal-study
#18
A D M Koopman, F Rutters, S P Rauh, G Nijpels, J J Holst, J W Beulens, M Alssema, J M Dekker
We conducted the first prospective observational study in which we examined the association between incretin responses to an oral glucose tolerance test (OGTT) and mixed meal test (MMT) at baseline and changes in fasting glucose levels 7 years later, in individuals who were non-diabetic at baseline. We used data from the Hoorn Meal Study; a population-based cohort study among 121 subjects, aged 61.0±6.7y. GIP and GLP-1 responses were determined at baseline and expressed as total and incremental area under the curve (tAUC and iAUC)...
2018: PloS One
https://www.readbyqxmd.com/read/29323755/direct-acting-antiviral-regimens-are-safe-and-effective-in-the-treatment-of-hepatitis-c-in-simultaneous-liver-kidney-transplant-recipients
#19
Anupama U Nookala, James Crismale, Thomas Schiano, Helen Te, Joseph Ahn, Suzanne Robertazzi, Colleen Rodigas, Rohit Satoskar, Mandip Kc, Mohamed Hassan, Coleman Smith
Hepatitis C (HCV) remains the single most common etiology of end-stage liver disease leading to simultaneous liver/kidney transplant (SLKT) and has worse post transplant survival compared to non-HCV patients. We aim to assess the effectiveness and tolerance of the all-oral direct acting antiviral (DAA) agents with or without ribavirin (RBV) in the treatment of HCV recurrence post SLKT. 34 patients were studied retrospectively, composed predominantly of treatment-naïve (73.5%) non-Caucasian (61.8%) males (82...
January 11, 2018: Clinical Transplantation
https://www.readbyqxmd.com/read/29323627/a-phase-3-multicenter-prospective-open-label-study-to-evaluate-the-safety-of-a-single-dose-of-secnidazole-2%C3%A2-g-for-the-treatment-of-women-and-postmenarchal-adolescent-girls-with-bacterial-vaginosis
#20
Steven E Chavoustie, Janet K Gersten, Milroy J Samuel, Jane R Schwebke
BACKGROUND: A novel formulation of secnidazole is under development in the United States for the treatment of bacterial vaginosis (BV). Efficacy and safety of other formulations of secnidazole have been reported. The objective of this study is to evaluate the safety of a single-dose oral granule formulation of secnidazole in a U.S. population of women with BV. METHODS: In this open-label study, patients were enrolled based on the following criteria: off-white, thin, homogeneous vaginal discharge; vaginal pH ≥4...
January 11, 2018: Journal of Women's Health
keyword
keyword
82802
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"